Rainbow Coral Corp (RBCC) 0.0360 $RBCC
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), AMGN: 157.68 (-3.17)
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), VRX: 134.21 (+2.31), BMY: 57.95 (+0.15)
RBCC 3D Bioprinting Partner Awarded Prestigious Grant
Business Wire - Thu Jul 31, 5:54AM CDT
The joint venture of Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D), moved significantly closer to its funding goals this week thanks to a prestigious research grant from the National Institutes of Health.
ABT: 43.81 (-0.78), AMGN: 157.68 (-3.17)
RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
Business Wire - Wed Jul 02, 4:00AM CDT
Work continues on a new injectable, sustained-release technology that Rainbow Coral Corp. (OTCBB: RBCC) hopes can help prevent a deadly epidemic of prescription narcotic overdoses.
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), VRX: 134.21 (+2.31), BMY: 57.95 (+0.15)
RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology
Business Wire - Thu Jun 26, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone, new research into the drug's potential could soon dramatically expand the drug's market and usage.
RBCC to Increase Investment in 3D Bioprinting Innovation
Business Wire - Tue Mar 25, 9:18AM CDT
As demand for new cellular research innovations continues to soar worldwide, Rainbow Biosciences, the biotechnology division of Rainbow Coral Corp. (OTCBB: RBCC), is increasing its investment in the marketing and development of a breakthrough 3D bioprinting technology.
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), AMGN: 157.68 (-3.17)
RBCC: Analyst Rates n3D a Leading Stakeholder in Explosive Bioprinting Industry
Business Wire - Thu Mar 06, 4:00AM CST
A new research publication lists Rainbow Coral Corp. (OTCBB: RBCC) Nano3D Biosciences (n3D) as a leading stakeholder in an industry forecast to be worth $10 billion by 2030.
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), AMGN: 157.68 (-3.17)
RBCC: New Innovations Spur Demand for 3D Printing in Medicine
Business Wire - Thu Feb 20, 4:00AM CST
As Rainbow Coral Corp. (OTCBB: RBCC) works to market and develop an innovative new 3D bioprinting system, new 3D printing innovations are generating massive new demand for the technology from patients and doctors alike in the medical industry.
New Product Puts RBCC on Leading Edge of Organ Regeneration Research
Business Wire - Tue Feb 18, 4:00AM CST
The 3D printing of functional human organs could be a reality within the next decade, and Rainbow Coral Corp. (OTCBB: RBCC) is helping to lead the bioprinting revolution now underway.
RBCC Seeks Out Capital Partners for 3D Bioprinting Expansion
Business Wire - Thu Feb 06, 4:00AM CST
Rainbow Bioscience, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), announced today that it is seeking out new capital partners to help expand marketing and streamline development on the BiO Assay, a 3D bioprinting system poised to potentially revolutionize the drug development industry.
CVBF: 15.55 (-0.13)
RBCC and N3D Continue Strong Promotional Push With MAD Scientist Contest
Business Wire - Wed Sep 18, 4:00AM CDT
As part of their ongoing efforts to publicize the breakthrough capabilities of the new Bio-Assembler 3D cell culturing system, Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner Nano3D Biosciences (n3D) will reanimate last year's highly successful MAD Scientist Contest to help introduce a new crop of bio-researchers to the device.
Scientific Journal Boosts Bio-Assembler's Market Potential
Business Wire - Thu Sep 12, 4:00AM CDT
Another high-profile piece of reporting on the Bio-Assembler, a 3-D cell culturing system being developed and marketed by Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D), was published today: this time in Nature Protocols, an online journal of laboratory protocols for bench researchers.
Nature.com Endorses RBCC Partner Technology
Business Wire - Wed Sep 04, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D) work to spread the word about the revolutionary magnetic Bio-Assembler, the innovative new technology's profile received a boost recently when it was featured alongside other exciting breakthroughs in the Nature.com marketplace.
RBCC Partner n3D's Cell Culture Technology Could Lead to New Cancer Breakthroughs
Business Wire - Wed Aug 28, 4:00AM CDT
Three-dimensional cell-culturing technology developed and marketed by Nano3D Biosciences (n3D) and Rainbow Biosciences, a biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), could hold the key to gaining new insights into the growth and spread of cancer cells.
RBCC and n3D Market New iPhone App to Dramatically Shorten Drug Toxicity Testing
Business Wire - Wed Aug 21, 4:00AM CDT
Biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner Nano3D Biosciences (n3D) are combining on the worldwide marketing and distribution of a new technology that makes testing a drug's potency and toxicity faster and easier.
AAPL: 114.18 (+1.36)
RBCC Narrows Search for Medical Business Consultant
Business Wire - Wed Aug 14, 3:59AM CDT
Fast-growing biotechnology providers Rainbow Coral Corp. (OTCBB: RBCC) announced today that it has narrowed its international search for a medical business director.
RBCC Initiates Search for Medical Business Consultant
Business Wire - Thu Aug 08, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to expand its biotechnology initiatives internationally, the company is seeking a medical business director to help the company penetrate the international personalized medicine industry.
RBCC Seeks Out New Opportunities North of the Border
Business Wire - Tue Jul 30, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) continues its aggressive push into the $232 billion personalized medicine market, the company is seeking out promising opportunities in a new, potentially lucrative territory: Canada.
RBCC Partner n3D BioSciences Unveils Top MAD Scientists
Business Wire - Tue Jul 23, 4:00AM CDT
In a successful bid to introduce its groundbreaking 3D cell culturing technology to a budding generation of "MAD" scientists, Rainbow Coral Corp. (OTCBB: RBCC) partner Nano3D BioSciences (n3D) has announced the winners of an intriguing scientific discovery competition, The MAD Scientist Contest by n3D.
RBCC: Insurance Companies, Researchers Drive Growth in Personalized Medicine
Business Wire - Thu Jul 11, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to develop new ways to capture a share of the fast-growing, $232 billion personalized medicine market, molecular pathology tests are rapidly transitioning from the laboratory to the clinic.
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), AMGN: 157.68 (-3.17)
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), VRX: 134.21 (+2.31), BMY: 57.95 (+0.15)
RBCC 3D Bioprinting Partner Awarded Prestigious Grant
Business Wire - Thu Jul 31, 5:54AM CDT
The joint venture of Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D), moved significantly closer to its funding goals this week thanks to a prestigious research grant from the National Institutes of Health.
ABT: 43.81 (-0.78), AMGN: 157.68 (-3.17)
RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
Business Wire - Wed Jul 02, 4:00AM CDT
Work continues on a new injectable, sustained-release technology that Rainbow Coral Corp. (OTCBB: RBCC) hopes can help prevent a deadly epidemic of prescription narcotic overdoses.
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), VRX: 134.21 (+2.31), BMY: 57.95 (+0.15)
RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology
Business Wire - Thu Jun 26, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone, new research into the drug's potential could soon dramatically expand the drug's market and usage.
RBCC to Increase Investment in 3D Bioprinting Innovation
Business Wire - Tue Mar 25, 9:18AM CDT
As demand for new cellular research innovations continues to soar worldwide, Rainbow Biosciences, the biotechnology division of Rainbow Coral Corp. (OTCBB: RBCC), is increasing its investment in the marketing and development of a breakthrough 3D bioprinting technology.
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), AMGN: 157.68 (-3.17)
RBCC: Analyst Rates n3D a Leading Stakeholder in Explosive Bioprinting Industry
Business Wire - Thu Mar 06, 4:00AM CST
A new research publication lists Rainbow Coral Corp. (OTCBB: RBCC) Nano3D Biosciences (n3D) as a leading stakeholder in an industry forecast to be worth $10 billion by 2030.
ABT: 43.81 (-0.78), BIIB: 305.43 (-12.55), AMGN: 157.68 (-3.17)
RBCC: New Innovations Spur Demand for 3D Printing in Medicine
Business Wire - Thu Feb 20, 4:00AM CST
As Rainbow Coral Corp. (OTCBB: RBCC) works to market and develop an innovative new 3D bioprinting system, new 3D printing innovations are generating massive new demand for the technology from patients and doctors alike in the medical industry.
New Product Puts RBCC on Leading Edge of Organ Regeneration Research
Business Wire - Tue Feb 18, 4:00AM CST
The 3D printing of functional human organs could be a reality within the next decade, and Rainbow Coral Corp. (OTCBB: RBCC) is helping to lead the bioprinting revolution now underway.
RBCC Seeks Out Capital Partners for 3D Bioprinting Expansion
Business Wire - Thu Feb 06, 4:00AM CST
Rainbow Bioscience, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), announced today that it is seeking out new capital partners to help expand marketing and streamline development on the BiO Assay, a 3D bioprinting system poised to potentially revolutionize the drug development industry.
CVBF: 15.55 (-0.13)
RBCC and N3D Continue Strong Promotional Push With MAD Scientist Contest
Business Wire - Wed Sep 18, 4:00AM CDT
As part of their ongoing efforts to publicize the breakthrough capabilities of the new Bio-Assembler 3D cell culturing system, Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner Nano3D Biosciences (n3D) will reanimate last year's highly successful MAD Scientist Contest to help introduce a new crop of bio-researchers to the device.
Scientific Journal Boosts Bio-Assembler's Market Potential
Business Wire - Thu Sep 12, 4:00AM CDT
Another high-profile piece of reporting on the Bio-Assembler, a 3-D cell culturing system being developed and marketed by Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D), was published today: this time in Nature Protocols, an online journal of laboratory protocols for bench researchers.
Nature.com Endorses RBCC Partner Technology
Business Wire - Wed Sep 04, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D) work to spread the word about the revolutionary magnetic Bio-Assembler, the innovative new technology's profile received a boost recently when it was featured alongside other exciting breakthroughs in the Nature.com marketplace.
RBCC Partner n3D's Cell Culture Technology Could Lead to New Cancer Breakthroughs
Business Wire - Wed Aug 28, 4:00AM CDT
Three-dimensional cell-culturing technology developed and marketed by Nano3D Biosciences (n3D) and Rainbow Biosciences, a biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), could hold the key to gaining new insights into the growth and spread of cancer cells.
RBCC and n3D Market New iPhone App to Dramatically Shorten Drug Toxicity Testing
Business Wire - Wed Aug 21, 4:00AM CDT
Biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner Nano3D Biosciences (n3D) are combining on the worldwide marketing and distribution of a new technology that makes testing a drug's potency and toxicity faster and easier.
AAPL: 114.18 (+1.36)
RBCC Narrows Search for Medical Business Consultant
Business Wire - Wed Aug 14, 3:59AM CDT
Fast-growing biotechnology providers Rainbow Coral Corp. (OTCBB: RBCC) announced today that it has narrowed its international search for a medical business director.
RBCC Initiates Search for Medical Business Consultant
Business Wire - Thu Aug 08, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to expand its biotechnology initiatives internationally, the company is seeking a medical business director to help the company penetrate the international personalized medicine industry.
RBCC Seeks Out New Opportunities North of the Border
Business Wire - Tue Jul 30, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) continues its aggressive push into the $232 billion personalized medicine market, the company is seeking out promising opportunities in a new, potentially lucrative territory: Canada.
RBCC Partner n3D BioSciences Unveils Top MAD Scientists
Business Wire - Tue Jul 23, 4:00AM CDT
In a successful bid to introduce its groundbreaking 3D cell culturing technology to a budding generation of "MAD" scientists, Rainbow Coral Corp. (OTCBB: RBCC) partner Nano3D BioSciences (n3D) has announced the winners of an intriguing scientific discovery competition, The MAD Scientist Contest by n3D.
RBCC: Insurance Companies, Researchers Drive Growth in Personalized Medicine
Business Wire - Thu Jul 11, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to develop new ways to capture a share of the fast-growing, $232 billion personalized medicine market, molecular pathology tests are rapidly transitioning from the laboratory to the clinic.
